Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 23, 2007. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held in GSK Ordinary Share ADRs within the US Retirement Savings Plan. Consequently, there was an increase in the notional allocation of Ordinary Share ADRs on October 19, 2007, at a price of $50.76 per ADR share for Dr. R G Greig.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 19, 2007.
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs.
- Price per ADR: $50.76.
- Individual Involved: Dr. R G Greig.
- Plan Involved: US Retirement Savings Plan.